Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 13/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17974916 | 0.82 | MAOB (0.41) | NR1H2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17974974 | 0.80 | TSHR (0.52) | NR1H2ALDH1A1TSHR | |
| SCHEMBL8126449 | 0.79 | NR1H2 (0.42) | NR1H2ALDH1A1TSHRNR1I2 | |
| SCHEMBL17974973 | 0.79 | KCNA5 (0.44) | CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20945461 | 0.78 | NR1H2 (0.58) | NR1H2NR1I2 | |
| SCHEMBL17974966 | 0.78 | SLC2A1 (0.50) | NR1H2ALDH1A1TSHRNR1H3NR1I2 | |
| SCHEMBL17974808 | 0.77 | NR1H3 (0.40) | NR1H2ALDH1A1TSHRNR1H3 | |
| SCHEMBL17974799 | 0.77 | PDK1 (0.42) | NR1H2 | |
| SCHEMBL17974801 | 0.77 | PDK1 (0.44) | NR1H2NR1H3 | |
| SCHEMBL17974911 | 0.76 | HTR7 (0.40) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-01-11 | — | — | US | disclosed |
| WO-2016123391-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202378-B2 | Therapeutic compounds and uses thereof | TAF1, TAF1L, TAF1B | NR1H2 2327/4885ALDH1A1 2132/4885TSHR 1358/4885 |
| US-20180009805-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | TAF1, TAF1L, TAF1B | NR1H2 2327/4885ALDH1A1 2132/4885TSHR 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.